Chasing the Unexpected (Nyla)

Chapter 349

“In the past year, our team has worked tirelessly, delving deep into the mechanisms of cancer and exploring new treatment strategies. Today, I am proud to announce that we’ve developed a ‘Long–acting Drug“,” Brendan said, his voice brimming with pride.

“This ‘Long–acting Drug‘ not only exhibits a high level of specificity, precisely targeting cancer cells, but it also maintains therapeutic effects in the body for an extended period. This means cancer patients can expect longer survival times and an improved quality of life.”

Brendan’s announcement was met with enthusiastic applause and

cheers from the audience.

As Brendan finished his speech, other researchers began presenting their findings.

Caroline was the fifth speaker. Dressed in a simple white lab coat with her hair neatly tied back, she projected a professional and capable image.

She started by displaying a series of detailed experimental data charts.

Pointing to the data on the screen, she explained, “These are the results of the in vitro and in vivo experiments we’ve conducted over the past few months on the ‘Long–acting Drug‘.

can see that the

in inhibiting the growth and spread

and videos of

Chapter 340

+25 BONUS

‘Long–acting Drug‘, the tumors in these animals have significantly reduced in size, and no major side effects. have been observed. This further confirms

generated great interest among the audience, with many people eager to learn more about the

acting Drug“.

answered each

progressed, discussions about the “Long–acting Drug” became increasingly intense. Even after the conference concluded, the audience seemed eager for

focused on drug research. advancements. High–profile figures from Saintornia were also in attendance. Drug development required significant funding, and

research.

over to Nyla with a smile and asked, “Nyla, how did I do?

her head and answered seriously, “Not at

abandoned her recommendation to stay in academia and returned to

that